Adrim

Adrim

doxorubicin

Manufacturer:

Fresenius Kabi

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Doxorubicin HCl
Indications/Uses
To produce regression in neoplastic conditions eg, acute lymphoblastic & acute myeloblastic leukaemias, malignant lymphomas of both Hodgkin's & non-Hodgkin's type, carcinoma of the breast, lung, bladder, thyroid as well as ovarian carcinoma, bone & soft tissue sarcomas, neuroblastoma & Wilm's tumour.
Dosage/Direction for Use
60-75 mg/m2 as single IV inj every 3 wk, or 20-30 mg/m2 daily for 3 days, repeated every 3-4 wk.
Contraindications
Marked myelosuppression induced by previous chemotherapy or radiotherapy, patients who received cumulative doses of anthracyclines. Pregnancy, lactation.
Special Precautions
Hepatic impairment.
Adverse Reactions
Myelosuppression, cardiac toxicity, atrial & ventricular dysrhythmias; toxic myocarditis or pericarditis-myocarditis syndrome; cardiomyopathy; alopecia, nausea & vomiting. Mucositis, anorexia & diarrhoea, phlebosclerosis, facial flushing, fever, chills & urticaria, anaphylaxis, cardiac toxicity.
Drug Interactions
May potentiate the toxicity of other anticancer therapies. Exacerbation of cyclophosphamide-induced hemorrhagic cystitis & enhancement of the hepatotoxicity of 6-mercaptopurine.
ATC Classification
L01DB01 - doxorubicin ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.
Presentation/Packing
Form
Adrim inj 50 mg/25 mL
Packing/Price
1's
Form
Adrim inj 10 mg/5 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in